Provided By GlobeNewswire
Last update: Feb 5, 2025
HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will host an in-person analyst day at the New York Marriott Marquis on February 12, 2025, at 2:00 p.m. ET.
Read more at globenewswire.comNASDAQ:FBLG (5/30/2025, 3:48:41 PM)
0.73
-0.02 (-2.67%)
Find more stocks in the Stock Screener